molecules of the month

RevMed KRASG12C Tricomplex Inhibitor

KRAS(G12C)ON-cyclophilin A tri-complex inh.

overcomes KRAS resist. mut. in PDX model

natural product related (sanglifehrin); undiscl.


Revolution Medicines, Redwood City, CA

RM-018 revmed tricomplex kras on inhibitor structure cyclophilin recruiter revolution medicines drug hunter molecules of the year
2 mins read

The Revolution Medicines KRASG12C inhibitor, RM-018, “glues” KRASG12C to the highly abundant chaperone protein, cyclophilin A, in a tri-complex (KRAS- inhibitor-cyclophilin A) stabilized by protein-protein interactions. An undisclosed molecule in their pipeline with a related mechanism, RMC-6291, has been reported to be orally bioavailable in multiple species, with oral activity in PDX models. KRAS is a driver of cancer cell growth, and mutants including KRASG12C have been hot targets due to the newfound ability to drug them selectively over wild type KRAS, which is important for healthy cell division. The first KRASG12C inhibitor, sotorasib, was approved in 2021. While GTP-OFF inhibitors of KRASG12C which bind to a switch-II have demonstrated clinical efficacy (including 2020 Small Molecule of the Year Finalist,…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: